Retention of androgen receptor (AR) signalling in castrate-resistant prostate malignancy (CRPC) shows the requirement for the development of more effective AR targeting therapies. opinions on the gene, but is definitely insufficient to maintain cell growth as proved by proclaimed anti-proliferative effects in FOXA1 knockdown cells. In all, our data suggests that AR-Vs are dependent on… Continue reading Retention of androgen receptor (AR) signalling in castrate-resistant prostate malignancy (CRPC)